NCT05645536 2026-01-12Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA StudyTolmar Inc.Phase 3 Enrolling by invitation250 enrolled
NCT03099174 2025-06-24This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast CancerBoehringer IngelheimPhase 1 Completed133 enrolled 26 charts
NCT01684215 2020-11-23A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast CancerPfizerPhase 2 Completed61 enrolled 45 charts
NCT02093351 2019-10-02To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid CancerAstraZenecaPhase 1 Completed79 enrolled 35 charts
NCT00062751 2011-04-15Study Evaluating Temsirolimus (CCI-779) In Breast NeoplasmsWyeth is now a wholly owned subsidiary of PfizerPhase 2 Completed108 enrolled 4 charts